Guardant Health (GH) is trading higher as the market digests renewed bullish sell-side positioning, including a recent note that named the stock a top pick and raised its price target substantially. With no major new regulatory decision or earnings release today, the price action appears driven by analyst conviction around accelerating adoption of Guardant’s screening and oncology franchises and the path to improving margins.

The timing is notable because Guardant’s next earnings report is approaching (scheduled for April 29, 2026). Into the print, investors are positioning around 2026 execution: company-level revenue outlook of about $1.25B–$1.28B and the expected ramp of Shield colorectal cancer screening, which management has highlighted as a major growth driver for 2026.

Key near-term catalysts are (1) any update on Shield volumes, payer mix, and commercialization efficiency; (2) progress in oncology test growth and biopharma demand; and (3) margin trajectory as the company scales and manages cost structure. A large move around the April 29 report is likely if Guardant signals faster-than-expected Shield revenue ramp or improves full-year profitability expectations.